Skip to main content
. 2022 Feb 21;79(4):349–358. doi: 10.1001/jamaneurol.2021.5578

Figure 1. Risk of Recurrent Stroke.

Figure 1.

Relative risk (RR) of recurrent stroke with more intensive vs less intensive low-density lipoprotein cholesterol–lowering statin-based therapies among patients with stroke. Different sizes of markers indicate the different weights used for pooled analysis. CARE indicates the Cholesterol and Recurrent Events Study; FOURIER, Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Patients With Elevated Risk; HPS, Heart Protection Study; IMPROVE-IT, Improved Reduction of Outcomes: Vytorin Efficacy International Trial; J-STARS, Japan Statin Treatment Against Recurrent Stroke; LIPID, Long-term Intervention with Pravastatin in Ischaemic Disease; ODYSSEY OUTCOMES, Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab; PCSK9, proprotein convertase subtilisin/kexin type 9; PODCAST, Prevention of Decline in Cognition after Stroke Trial; SPARCL, Stroke Prevention by Aggressive Reduction in Cholesterol Levels; and TST, Treat Stroke to Target.